Synthetic peptide immunotherapeutic: Began Phase I trial in 19-25 patients to assess safety, dosing, and immunogenicity. The immunostimulatory peptides are link

United Biomedical Inc., Hauppauge, N.Y. Product: Synthetic peptide immunotherapeutic Indication: Androgen-dependent prostate cancer Status: Began Phase I trial in 19-25 patients to assess safety, dosi...